“…The most commonly used criteria for the classification of IIMs are those that were proposed by Bohan and Peter in 1975 [1]. From a clinico-pathological perspective, the IIMs fall into six categories: (1) dermatomyositis (DM; juvenile, adult), (2) polymyositis (PM; T-cell mediated, eosinophilic, granulomatous), (3) overlap syndromes (with DM, with PM, with sIBM/hIBM), (4) cancer-associated myositis, (5) inclusion body myositis (IBM), and (6) other forms (focal: orbital myositis, localised nodular myositis, inflammatory pseudotumor; diffuse: macrophagic myofasciitis, necrotizing autoimmune myopathy (NAM), infantile myositis) [2][3][4][5][6][7][8][9][10][11][12][13][14][15][16]. Although this clinico-pathological subdivision has a predictive value in prognosis and in therapy, according to our rising knowledge of the autoantibodies, this system seems to be worn out.…”